Dominique N Price1,2, Nitesh K Kunda1,3, Rajaun Ellis4,5, Pavan Muttil6. 1. Department of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico, Health Sciences Center, Albuquerque, New Mexico, 87131, USA. 2. Biomedical Sciences Graduate Program, University of New Mexico, Health Sciences Center, Albuquerque, New Mexico, 87131, USA. 3. Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Jamaica, New York, 11439, USA. 4. Health Sciences Center, University of New Mexico, Albuquerque, New Mexico, 87131, USA. 5. Nova Southeastern University, Fort Lauderdale, Florida, 33314, USA. 6. Department of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico, Health Sciences Center, Albuquerque, New Mexico, 87131, USA. pmuttil@salud.unm.edu.
Abstract
PURPOSE: Loss of vaccine potency due to extreme temperature exposure during storage and transport remains a significant obstacle to the success of many vaccines, including the Bacille Calmette-Guérin (BCG) vaccine, the only vaccine available against Mycobacterium tuberculosis. BCG is a live, attenuated vaccine requiring refrigerated storage for viability. In this study, we formulated a temperature-stable BCG dry powder using the spray drying technique. METHODS: We employed a factorial design to optimize our formulation of stabilizing excipients that included L-leucine, bovine serum albumin, polyvinylpyrrolidone, mannitol, and trehalose. Powders were characterized for their particle size, yield, water retention and uptake, glass transition temperature, and aerosol performance. Three optimal powder carrier mixtures were selected from the factorial design for BCG incorporation based on their stability-promoting and powder flow characteristics. Vaccine powders were also assessed for BCG viability and in vivo immunogenicity after long-term storage. RESULTS: Live BCG was successfully spray-dried using the optimized carriers. Dry powder BCG showed no loss in viability (25°C, up to 60% relative humidity; RH) and ~2-log loss in viability (40°C, 75% RH) after one year of storage. The aerodynamic size of the powders was in the respirable range. Further, when healthy mice were immunized intradermally with reconstituted BCG powders (storage for 2 years), the vaccine retained its immunogenicity. CONCLUSION: We developed a spray-dried BCG vaccine that was viable and antigenic after long-term storage. To our knowledge, this is a first study to show room temperature stability of live BCG vaccine without any loss in viability for 12 months.
PURPOSE: Loss of vaccine potency due to extreme temperature exposure during storage and transport remains a significant obstacle to the success of many vaccines, including the Bacille Calmette-Guérin (BCG) vaccine, the only vaccine available against Mycobacterium tuberculosis. BCG is a live, attenuated vaccine requiring refrigerated storage for viability. In this study, we formulated a temperature-stable BCG dry powder using the spray drying technique. METHODS: We employed a factorial design to optimize our formulation of stabilizing excipients that included L-leucine, bovine serum albumin, polyvinylpyrrolidone, mannitol, and trehalose. Powders were characterized for their particle size, yield, water retention and uptake, glass transition temperature, and aerosol performance. Three optimal powder carrier mixtures were selected from the factorial design for BCG incorporation based on their stability-promoting and powder flow characteristics. Vaccine powders were also assessed for BCG viability and in vivo immunogenicity after long-term storage. RESULTS: Live BCG was successfully spray-dried using the optimized carriers. Dry powder BCG showed no loss in viability (25°C, up to 60% relative humidity; RH) and ~2-log loss in viability (40°C, 75% RH) after one year of storage. The aerodynamic size of the powders was in the respirable range. Further, when healthy mice were immunized intradermally with reconstituted BCG powders (storage for 2 years), the vaccine retained its immunogenicity. CONCLUSION: We developed a spray-dried BCG vaccine that was viable and antigenic after long-term storage. To our knowledge, this is a first study to show room temperature stability of live BCG vaccine without any loss in viability for 12 months.
Authors: Tomás Sou; Els N Meeusen; Michael de Veer; David A V Morton; Lisa M Kaminskas; Michelle P McIntosh Journal: Trends Biotechnol Date: 2011-01-20 Impact factor: 19.536
Authors: Dominique N Price; Donna F Kusewitt; Christopher A Lino; Amber A McBride; Pavan Muttil Journal: PLoS Pathog Date: 2016-05-06 Impact factor: 6.823
Authors: Mellissa Gomez; Joseph McCollum; Hui Wang; Mani Ordoubadi; Chester Jar; Nicholas B Carrigy; David Barona; Isobel Tetreau; Michelle Archer; Alana Gerhardt; Chris Press; Christopher B Fox; Ryan M Kramer; Reinhard Vehring Journal: Int J Pharm Date: 2020-12-02 Impact factor: 5.875
Authors: Mellissa Gomez; Michelle Archer; David Barona; Hui Wang; Mani Ordoubadi; Shabab Bin Karim; Nicholas B Carrigy; Zheng Wang; Joseph McCollum; Chris Press; Alana Gerhardt; Christopher B Fox; Ryan M Kramer; Reinhard Vehring Journal: Eur J Pharm Biopharm Date: 2021-03-19 Impact factor: 5.589
Authors: Mellissa Gomez; Mushtaq Ahmed; Shibali Das; Joseph McCollum; Leah Mellett; Rosemary Swanson; Ananya Gupta; Nicholas B Carrigy; Hui Wang; David Barona; Shital Bachchhav; Alana Gerhardt; Chris Press; Michelle C Archer; Hong Liang; Emilie Seydoux; Ryan M Kramer; Philip J Kuehl; Reinhard Vehring; Shabaana A Khader; Christopher B Fox Journal: Front Pharmacol Date: 2022-01-21 Impact factor: 5.810